Multi-Platform Deal With Genentech Ushers In A New Partnership Era For MXCT

Research evidence excerpt

Multi-Platform Deal With Genentech Ushers In A New Partnership Era For MXCT

TD Cowen MaxCyte

Global Research July 21, 2026

Enterprise Structure Drives Multi-Program Exposure, But Discussions Remain Focused on

Earlier-Stage Assets

A key differentiator for today's announcement versus a traditional SPL is the breadth of program

exposure. Management indicated that beyond the two existing Ph1 programs, the agreement

is intended to support future preclinical cell therapy programs across Genentech’s portfolio,

allowing Genentech to utilize MaxCyte’s platform without conducting technology evaluations on

a program-by-program basis. Importantly, management noted that displacement opportunities

are generally most feasible during preclinical development and Ph1, while displacement

becomes more difficult in later-stage settings. As a result, we think the agreement (and any

potential deals using a similar approach) will likely focus on existing early clinical programs and

future preclinical assets rather than more mature development-stage programs.

Breadth Of Platform Was Instrumental To Winning The Business

Beyond electroporation, management highlighted MaxCyte’s expanded technology portfolio

as an important factor in securing the agreement. The partnership includes access to multiple

electroporation systems, analytical offerings, and SeQure Dx capabilities. Management noted

that Genentech was seeking a platform partner rather than a product supplier and specifically

cited the breadth of MaxCyte’s portfolio, scientific support infrastructure, and analytical

capabilities as differentiating factors. We believe this reinforces the strategic rationale behind

MaxCyte’s investments in recent years to build a more comprehensive cell engineering platform